{
    "2021-08-24": [
        [
            {
                "time": "2023-10-18",
                "original_text": "Novartis (NVS) Kymriah Misses Primary Endpoint in NHL Study",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Kymriah",
                        "Misses",
                        "Primary Endpoint",
                        "NHL Study"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-10-18",
                "original_text": "Novartis provides update on BELINDA study investigating KymriahÂ® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma",
                "features": {
                    "keywords": [
                        "Novartis",
                        "BELINDA study",
                        "Kymriah",
                        "second-line treatment",
                        "aggressive B-cell non-Hodgkin lymphoma"
                    ],
                    "sentiment_score": 0.2,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}